Does the HNMT rs11558538 CT genotype reduce histamine breakdown and amplify histamine signaling?

Molecular mechanisms of impaired clearance

• The histamine N-methyltransferase (HNMT) rs11558538 CT heterozygous genotype (Thr105Ile), resulting from a C314T transition, is a functional loss-of-function variant that reduces intracellular histamine clearance.
• Substituting hydrophilic threonine with a bulkier, hydrophobic isoleucine on the protein's surface destabilizes the folded enzyme, leading to protein misfolding and accelerated proteasomal degradation.
• This reduction in stable, active enzyme abundance decreases the apparent maximum velocity ($V_{\max}$) of intracellular histamine degradation without significantly altering substrate binding affinity ($K_m$).
• Due to a clear gene-dosage effect, carriers of the heterozygous CT genotype experience a moderate 30% to 40% reduction in functional histamine degradation capacity.

Systemic impact during immune activation

• When histamine-producing immune cells, such as mast cells and basophils, become active, they release stored histamine into the local microenvironment to initiate inflammatory cascades.
• In individuals with the rs11558538 CT genotype, the genetically compromised clearance system fails to keep pace with this localized influx, causing histamine to accumulate.
• Slower enzymatic degradation prolongs local histamine receptor activation, amplifying downstream signaling and tissue sensitivity, which clinically exacerbates allergic conditions such as asthma, allergic rhinitis, and atopic dermatitis.

Bottom line

• The HNMT rs11558538 CT genotype causes a 30% to 40% reduction in histamine clearance due to enzyme destabilization, which directly amplifies and prolongs localized inflammatory signaling when histamine-producing immune cells are active.